Compare HBIO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | ATNM |
|---|---|---|
| Founded | 1901 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 31.7M |
| IPO Year | 2000 | 2013 |
| Metric | HBIO | ATNM |
|---|---|---|
| Price | $8.10 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $4.50 |
| AVG Volume (30 Days) | 20.2K | ★ 180.2K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $116,176,000.00 | $90,000.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | ★ N/A | $1.73 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.38 | $0.74 |
| 52 Week High | $8.40 | $1.74 |
| Indicator | HBIO | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.44 | 74.47 |
| Support Level | $5.91 | $0.98 |
| Resistance Level | $8.40 | $1.38 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 73.29 | 83.78 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.